Publication
Characteristics of IEF, SDS and SAR-PAGE of Cuba EPO biosimilar
| dc.contributor.author | Tavares, Ana Sofia | |
| dc.contributor.author | Ruivo, João | |
| dc.contributor.author | Oca, Rodny Montes de | |
| dc.contributor.author | Martínez Brito, Dayamín | |
| dc.contributor.author | Torres, Mirta | |
| dc.date.accessioned | 2016-02-15T11:20:30Z | |
| dc.date.available | 2016-02-15T11:20:30Z | |
| dc.date.issued | 2015-03 | |
| dc.description.abstract | EPO is a glycoprotein produced in the kidney, which stimulates the division and differentiation of red cells in the bone marrow. Erythropoietin is available as a therapeutic agent produced by recombinant DNA technology in mammalian cell culture into which the human EPO gene has been transfected. Biosimilar Epoetins are mostly erythropoietins of the Epoetin alfa, beta or omega type, which are being produced at much lower cost due to expired patents. Recombinant human erythropoietin (rh-EPO) contains the identical amino acid sequence of natural EPO: 165 amino acids, with a molecular weight of 30,400 Da. Since glycosylation is not only dependent on the cell-line used for the expression of Epoetins but also on the entire biotechnological process the glycosylation patterns of biosimilars do not necessarily reflect the patterns of the originator compounds. Today biosimilar Epoetins are manufactured and distributed worldwide and under many different names. The use of recombinant EPOs for doping is prohibited because of its performance enhancing effect. The aim of the present study was to investigated whether biosimilar alpha r-HuEPO – ior®-EPOCIM, produced in Cuba and also available in other countries in all continents, could be differentiated from endogenous one by iso-electro-focusing plus double blotting, SDS-PAGE and SAR-PAGE for antidoping analysis. | pt_PT |
| dc.identifier.citation | Tavares AS, Ruivo J, Oca RM, Martínez Brito D, Torres M. Characteristics of IEF, SDS and SAR-PAGE of Cuba EPO biosimilar. In 33rd Manfred Donike Workshop on Doping Analysis, Cologne (Germany), 1-6 March, 2015. | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.21/5676 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | pt_PT |
| dc.subject | Erythropoietin | pt_PT |
| dc.subject | Recombinant DNA | pt_PT |
| dc.subject | Cuba | pt_PT |
| dc.title | Characteristics of IEF, SDS and SAR-PAGE of Cuba EPO biosimilar | pt_PT |
| dc.type | conference object | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | Colónia | pt_PT |
| person.familyName | Tavares | |
| person.givenName | Ana Sofia | |
| person.identifier.ciencia-id | 9D10-BB39-04DF | |
| person.identifier.orcid | 0000-0002-5335-7498 | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | conferenceObject | pt_PT |
| relation.isAuthorOfPublication | 13fb72b8-212a-4a99-84c3-9038d984d945 | |
| relation.isAuthorOfPublication.latestForDiscovery | 13fb72b8-212a-4a99-84c3-9038d984d945 |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- Characteristics of IEF, SDS and SAR-PAGE of cuba EPO biosimilar.pdf
- Size:
- 800.64 KB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: